InvestSMART

Antisense Therapeutics Limited (ASX: ANP) - Announcements

Current share price for ANP : $0.058 0.003 (4.92%)+

ASX company news and announcements for Antisense Therapeutics Limited (ANP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Antisense Therapeutics Limited (ANP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Antisense Therapeutics Limited (ANP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Antisense Therapeutics Limited (ANP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$52 Bonus and New Options Offer Prospectus 29 Nov 2016 9:33AM $0.041 $0.058 risen by 41.46%
$52 Receipt of R&D Tax Incentive payment 15 Nov 2016 9:04AM $0.040 $0.058 risen by 45%
$52 Results of Annual General Meeting 10 Nov 2016 3:44PM $0.033 $0.058 risen by 75.76%
$52 AGM Presentation and Questions on notice 10 Nov 2016 11:18AM $0.038 $0.058 risen by 52.63%
$52 ATL1102 for Multiple Sclerosis - Progress Update 4 Nov 2016 9:01AM $0.040 $0.058 risen by 45%
$52 Appendix 4G - Corporate Governance Statement 3 Nov 2016 5:14PM $0.040 $0.058 risen by 45%
$52 Appendix 4C - quarterly 31 Oct 2016 10:11AM $0.044 $0.058 risen by 31.82%
$52 Change of Director's Interest Notice (WG) 19 Oct 2016 9:04AM $0.043 $0.058 risen by 34.88%
$52 Capital Management Initiatives - Update 11 Oct 2016 3:34PM $0.048 $0.058 risen by 20.83%
$52 Less Than Marketable Parcel Share Sale Program 11 Oct 2016 3:30PM $0.048 $0.058 risen by 20.83%
$52 Notice of Annual General Meeting/Proxy Form/Annual Report 11 Oct 2016 3:20PM $0.048 $0.058 risen by 20.83%
$52 ATL1103 Higher Dose Study 11 Oct 2016 9:19AM $0.040 $0.058 risen by 45%
$52 Change of Director's Interest Notice (GP) 7 Sep 2016 9:53AM $0.040 $0.058 risen by 45%
$52 Company Update 26 Aug 2016 8:58AM $0.037 $0.058 risen by 56.76%
$52 Preliminary Final Report 25 Aug 2016 7:03PM $0.037 $0.058 risen by 56.76%
$52 Positive Results Achieved from ATL1103 Higher Dose Study 27 Jul 2016 9:15AM $0.041 $0.058 risen by 41.46%
$52 Appendix 4C - quarterly 18 Jul 2016 9:04AM $0.032 $0.058 risen by 81.25%
$52 ATL1103 Patent Update 13 Jul 2016 9:48AM $0.036 $0.058 risen by 61.11%
$52 ATL1103 Granted Orphan Drug Designation in Europe 28 Jun 2016 9:10AM $0.030 $0.058 risen by 93.33%
$52 ATL1102 for Multiple Sclerosis - Update 17 Jun 2016 9:56AM $0.034 $0.058 risen by 70.59%
$52 Antisense Technology Update 1 Jun 2016 1:16PM $0.039 $0.058 risen by 48.72%
$52 Company Strategy Update 24 May 2016 9:08AM $0.049 $0.058 risen by 18.37%
$52 Change in substantial holding from OPT 16 May 2016 11:30AM $0.059 $0.058 fallen by 1.69%
$52 Orphan Drug designation from FDA for ATL1103 in Acromegaly 12 May 2016 9:37AM $0.048 $0.058 risen by 20.83%
$52 ATL1103 Higher Dose Study - Update 9 May 2016 9:40AM $0.042 $0.058 risen by 38.10%

401 - 425 of 707 results

Page 17 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.